New effective treatments for people with psoriatic arthritis revealed at conference
Two new drugs could soon be available for people with psoriatic arthritis thanks to promising data presented at the Annual European Congress of Rheumatology.
One study showed that in people with active psoriatic arthritis who had not previously been prescribed an anti-TNF treatment, tofacitinib was better than a sham drug in response rates and change from baseline scores three months later. Benefits were seen as early as two weeks after treatment began and lasted for 12 months. No new safety risks were identified.
Another study found that in people with active psoriatic arthritis despite current or previous treatment with standard-of-care therapies, guselkumab resulted in improvement in joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.